

CHMP statistics: September 2016

Positive opinions on new medicines

New [non-orphan] medicines Orphan medicines Generics / hybrids / informed consent





Negative opinions on new medicines

Negative opinions 0**



Positive opinions on extensions of therapeutic indications



* Mysildecard (sildenafil), a generic of Revatio, received a positive opinion from the CHMP by written procedure in July 2016. This is reflected in the total number of positive opinions on new medicines for 2016.

**Ninlaro received a positive opinion at the September CHMP following a re-examination. Therefore the number of negative opinions for 2016 has been revised to 0.

